Swati Sathe, MD, Medical Director at CHDI Management/CHDI Foundation, discusses the crucial role biomarkers play within the Enroll-HD study by facilitating earlier intervention of Huntington disease (HD).
Enroll-HD, as Dr. Sathe explains, is a multicenter, longitudinal observational study that has enrolled over 20,000 participants worldwide. This participant group includes individuals with HD and those at-risk.
Studies nested in Enroll-HD, such as the HD Clarity study, the ImageClarity study, and multiple PET studies, all reinforce the need to learn more about the relationship between biomarkers and progression of HD in patients, according to Dr. Sathe.
For more information about CHDI Foundation, visit chdifoundation.org/
To learn more about HD and other rare neurological disorders, visit checkrare.com/diseases/neurology